ALLMedicine™ Familial Hypercholesterolemia Center

Jan 20th, 2022 - Sitosterolemia is a lipid disorder characterized by the accumulation of phytosterols in plasma and organs, caused by mutations in the ABCG5 and/or ABCG8 genes. The disease is frequently misdiagnosed and mistreated as familial hypercholesterolemia ...

Jan 14th, 2022 - Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder that elevates low-density lipoprotein cholesterol and increases the risk of premature atherosclerotic cardiovascular disease (ASCVD). However, despite their atherogenic lipid ...

Jan 14th, 2022 - Background Accurate measurement of the cholesterol within lipoprotein(a) (Lp[a]-C) and its contribution to low-density lipoprotein cholesterol (LDL-C) has important implications for risk assessment, diagnosis, and treatment of atherosclerotic card...

Jan 13th, 2022 - Purpose: Heterozygous Familial Hypercholesterolemia (HeFH) is a common genetic disease responsible for premature atherosclerosis. Therefore, early diagnosis and initiation of a treatment early as at the age of eight years old are recommended to re...

Jan 13th, 2022 - This is a two-part (1 year double-blind inclisiran versus placebo / 1 year open-label inclisiran) multicenter study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia ...

Dec 12th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Dec 18th, 2013 - Familial hypercholesterolemia.|2013|Teramoto T,Sasaki J,Ishibashi S,Birou S,Daida H,|diagnosis,etiology,prevention & control,diagnosis,etiology,prevention & control,diagnosis,prevention & control,

Jan 13th, 2022 - This is a two-part (1 year double-blind inclisiran versus placebo / 1 year open-label inclisiran) multicenter study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia ...

Jan 13th, 2022 - Purpose: Heterozygous Familial Hypercholesterolemia (HeFH) is a common genetic disease responsible for premature atherosclerosis. Therefore, early diagnosis and initiation of a treatment early as at the age of eight years old are recommended to re...

Dec 22nd, 2021 - Familial hypercholesterolemia is an autosomal co-dominant disorder resulting in abnormal LDL receptor function, profoundly elevated concentrations of low density lipoproteins, accelerated atherosclerosis and death by early adulthood. This disease ...

Nov 9th, 2021 - A ketogenic diet (KD) has recently gained popularity amongst the public due to its ability to induce rapid weight loss and for a number of other putative but unproven health benefits. Ketogenic diets also have proven efficacy in resistant cases of...

Oct 12th, 2021 - The FH Foundation CASCADE-FH Registry will implement an enrollment framework which is characterized by three possible points of contact: 1) Clinic enrollment 2) Self-enrollment through an online patient portal, and 3) Electronic Health Record (EHR...

Dec 22nd, 2021 - FDA finally approved inclisiran (Leqvio), making it the first small interfering RNA (siRNA) therapy to hit the market for reducing LDL cholesterol, Novartis announced on Wednesday. The PCSK9 inhibitor was handed an indication as an adjunct to diet...

Dec 22nd, 2021 - Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that results in elevated blood cholesterol levels and a markedly increased risk for atherosclerosis and premature coronary artery disease. Although it is commonly perceiv...

Oct 21st, 2021 - This transcript has been edited for clarity. Laurence Sperling, MD: Welcome to the Medscape InDiscussion podcast series on dyslipidemia. This is the first of six episodes. To launch this series today, we will focus on an extremely important topic:...

Sep 30th, 2021 - NEW YORK (Reuters Health) - Globally, familial hypercholesterolemia (FH) is diagnosed late, and control of LDL cholesterol in patients is far below recommendations, a new analysis shows. "Guideline-recommended LDL cholesterol concentrations are in...

Sep 24th, 2021 - The US Food and Drug Administration (FDA) has approved evolocumab (Repatha, Amgen), a PCSK9 inhibitor, for use as add-on treatment to diet alone or with other therapies for children 10 years of age and older with either heterozygous or homozygous ...